Compare LCNB & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | VYGR |
|---|---|---|
| Founded | 1877 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.1M | 194.0M |
| IPO Year | 1999 | 2015 |
| Metric | LCNB | VYGR |
|---|---|---|
| Price | $16.11 | $4.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 20.2K | ★ 808.0K |
| Earning Date | 04-30-2026 | 06-10-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | $6,445,000.00 | ★ $10,135,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | $71.77 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $2.65 |
| 52 Week High | $17.89 | $5.55 |
| Indicator | LCNB | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 33.73 | 54.31 |
| Support Level | $15.24 | $3.83 |
| Resistance Level | $16.44 | $4.43 |
| Average True Range (ATR) | 0.46 | 0.32 |
| MACD | -0.13 | 0.06 |
| Stochastic Oscillator | 9.01 | 39.72 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.